Please login to the form below

Not currently logged in
Email:
Password:

Corlanor

This page shows the latest Corlanor news and features for those working in and with pharma, biotech and healthcare.

Amgen agrees to take Cytokinetics' heart failure drug into phase III

Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics